What BQ.1 dominance means for Evusheld, bebtelovimab

With omicron subvariants BQ.1 and BQ.1.1 accounting for more than half of COVID-19 cases, at least two therapies are on the cusp of losing their mainstay status in the COVID-19 drug market. 

FDA probes severe hypocalcemia risk with Amgen’s osteoporosis drug

The FDA will investigate the risk of severe hypocalcemia that results in hospitalization and death with Amgen’s osteoporosis drug, Prolia (denosumab). 

Second study participant dies during Eisai’s Alzheimer’s drug trial

A second study participant has died possibly as a result of the experimental antibody drug, lecanemab, meant to treat Alzheimer’s, Science reported Nov. 27.

AAP recommends antibiotic alternatives during amoxicillin shortage

As the national amoxicillin shortage worsens, the American Academy of Pediatrics released a guidance Nov. 21 detailing its recommendations for alternative therapies. 

Mark Cuban in talks with hospitals to solve drug shortages

Mark Cuban is in talks with hospitals to identify generic drugs that often run in short supply, which he aims to make in a robotics-driven manufacturing plant currently in development in Dallas.

FDA approves most expensive drug on market

The FDA approved a hemophilia B drug with a list price of $3.5 million — which could save the healthcare system millions per patient according to drug maker CSL Behring.

Stanford researchers to test Paxlovid as a long COVID-19 treatment

Researchers from Stanford (Calif.) University are enrolling 200 participants in a phase 2 study to see if Paxlovid could be used to treat the millions of Americans experiencing long COVID-19, according to a Nov. 21 entry on clinicaltrials.gov. 

Pharma giants ditch Twitter after fake Eli Lilly tweet

After one fake tweet about Eli Lilly offering insulin for free went viral and the company’s shares plunged, 12 of the 18 biggest drugmakers that advertise on Twitter have cut their spending to $0, Endpoints News reported Nov. 21. 

Mark Cuban Cost Plus Drugs adds 82 drugs to portfolio

Mark Cuban’s online pharmacy now offers nearly 1,000 generics after adding 82 drugs to its repertoire, the company said Nov. 21. 

Inflation Reduction Act will restrict oncology drug development, Bristol-Myers Squibb CEO says

With tighter rules from the Inflation Reduction Act approaching, Bristol-Myers Squibb will cancel plans for some drug development programs and cancer treatments, the drugmaker’s CEO, Giovanni Caforio, MD, recently told the Financial Times. 

Older posts «

Explore the Archive